Figure 6.

Immunocompetent mouse model of HCC shows significant anti-tumour effect of vandetanib-radiation treatment over single therapy. Immunocompetent BALB/C mice were engrafted with BNL.1ME tumours and administered fractionated radiotherapy on days 17, 18, and 19 and/or vandetanib treatment on days 17–24. Tumour growth was measured in three dimensions until culling. (A) Tumour volume for all mice by treatment cohort. (B) Mean tumour volume. (C) Survival curve. Combined treatment was significant (p ≤ 0.001) with respect to tumour volume and significant (p ≤ 0.05) with respect to overall survival against both regimes and control. Volume growth curves are expressed as mean ± SEM and analyzed by extra sum-of-squares F test. Survival is represented by a Kaplan–Meier plot. Log-rank test. * p ≤ 0.05, *** p ≤ 0.005.